BACKGROUND: To assess different warranty periods following a normal myocardial perfusion SPECT based on patients' clinical characteristics and the type of stress performed. METHODS AND RESULTS: A study was done of 2,922 consecutive patients (62.9 ± 13 years; 53.4% women) with a normal stress-rest SPECT. The warranty period was defined as the period during which patients remained at a low risk (<1% events/year) of total mortality (TM), or hard events (HE) (cardiac death or non-fatal myocardial infarction). Of these patients, 2,051 were given an exercise myocardial perfusion imaging (Ex-MPI); 461 submaximal exercise plus dipyridamole (Ex+Dipy-MPI); and 410 dipyridamole (Dipy-MPI). During a mean follow-up of 5 ± 3.3 years, a significant reduction (P < .05) of the warranty period for TM (13.5, 9.6 and 8 months) and HE (34.8, 20.5 and 8.2 months) was observed, for Ex-MPI, Ex+Dipy-MPI and Dipy-MPI, respectively. Other warranty period determinants were the clinical variables of age, sex, diabetes and known coronary artery disease. An abnormal left ventricular ejection fraction on gated-SPECT also significantly shortened the warranty period for HE in patients undergoing Ex+Dipy-MPI (P = .001) or Dipy-MPI alone (P = .007). CONCLUSIONS: The warranty period for a normal stress-rest SPECT is highly variable since it is primarily determined by the type of stress, the patient's clinical characteristics and LVEF.
BACKGROUND: To assess different warranty periods following a normal myocardial perfusion SPECT based on patients' clinical characteristics and the type of stress performed. METHODS AND RESULTS: A study was done of 2,922 consecutive patients (62.9 ± 13 years; 53.4% women) with a normal stress-rest SPECT. The warranty period was defined as the period during which patients remained at a low risk (<1% events/year) of total mortality (TM), or hard events (HE) (cardiac death or non-fatal myocardial infarction). Of these patients, 2,051 were given an exercise myocardial perfusion imaging (Ex-MPI); 461 submaximal exercise plus dipyridamole (Ex+Dipy-MPI); and 410 dipyridamole (Dipy-MPI). During a mean follow-up of 5 ± 3.3 years, a significant reduction (P < .05) of the warranty period for TM (13.5, 9.6 and 8 months) and HE (34.8, 20.5 and 8.2 months) was observed, for Ex-MPI, Ex+Dipy-MPI and Dipy-MPI, respectively. Other warranty period determinants were the clinical variables of age, sex, diabetes and known coronary artery disease. An abnormal left ventricular ejection fraction on gated-SPECT also significantly shortened the warranty period for HE in patients undergoing Ex+Dipy-MPI (P = .001) or Dipy-MPI alone (P = .007). CONCLUSIONS: The warranty period for a normal stress-rest SPECT is highly variable since it is primarily determined by the type of stress, the patient's clinical characteristics and LVEF.
Authors: Rory Hachamovitch; Sean Hayes; John D Friedman; Ishac Cohen; Leslee J Shaw; Guido Germano; Daniel S Berman Journal: J Am Coll Cardiol Date: 2003-04-16 Impact factor: 24.094
Authors: Robert C Hendel; Daniel S Berman; Marcelo F Di Carli; Paul A Heidenreich; Robert E Henkin; Patricia A Pellikka; Gerald M Pohost; Kim A Williams Journal: J Am Coll Cardiol Date: 2009-06-09 Impact factor: 24.094
Authors: Jane A Simonsen; Oke Gerke; Charlotte K Rask; Mohammad Tamadoni; Anders Thomassen; Søren Hess; Allan Johansen; Hans Mickley; Lisette O Jensen; Jesper Hallas; Werner Vach; Poul F Høilund-Carlsen Journal: J Nucl Cardiol Date: 2013-03-01 Impact factor: 5.952
Authors: Leslee J Shaw; Robert Hendel; Salvador Borges-Neto; Michael S Lauer; Naomi Alazraki; Joy Burnette; Elizabeth Krawczynska; Manuel Cerqueira; Jamshid Maddahi Journal: J Nucl Med Date: 2003-02 Impact factor: 10.057
Authors: Machiel J M Ottenhof; Marisa C G Tjong Joe Wai; Hendrik J Boiten; Rebecca S Korbee; Roelf Valkema; Ron T van Domburg; Arend F L Schinkel Journal: J Nucl Cardiol Date: 2013-08-03 Impact factor: 5.952
Authors: Elizabeth Klodas; Todd D Miller; Timothy F Christian; David O Hodge; Raymond J Gibbons Journal: J Nucl Cardiol Date: 2003 Jan-Feb Impact factor: 5.952
Authors: Alan Rozanski; Heidi Gransar; James K Min; Sean W Hayes; John D Friedman; Louise E J Thomson; Daniel S Berman Journal: J Nucl Cardiol Date: 2013-12-31 Impact factor: 5.952
Authors: Robert J H Miller; Lien-Hsin Hu; Heidi Gransar; Julian Betancur; Evann Eisenberg; Yuka Otaki; Tali Sharir; Mathews B Fish; Terrence D Ruddy; Sharmila Dorbala; Marcelo Di Carli; Andrew J Einstein; Philipp A Kaufmann; Albert J Sinusas; Edward J Miller; Timothy Bateman; Guido Germano; Balaji K Tamarappoo; Damini Dey; Daniel S Berman; Piotr J Slomka Journal: Eur Heart J Cardiovasc Imaging Date: 2020-05-01 Impact factor: 6.875
Authors: Miguel Bernardes; Tiago S Vieira; Maria João Martins; Raquel Lucas; Lúcia Costa; Jorge G Pereira; Francisco Ventura; Elisabete Martins Journal: Biomed Res Int Date: 2017-05-03 Impact factor: 3.411